{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:09Z","timestamp":1791908409771,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06336-1","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:22:43Z","timestamp":1758954163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of hepatotoxicity associated with CDK4\/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-negative breast cancer"],"prefix":"10.1007","volume":"151","author":[{"given":"Nurullah","family":"\u0130lhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman","family":"Ba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiz","family":"Majidova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Alperen","family":"Tun\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Erdemo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu\u011fra","family":"\u00d6ztosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lker Nihat","family":"\u00d6kten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"issue":"6","key":"6336_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H et al (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89(6):806\u2013815. https:\/\/doi.org\/10.1038\/clpt.2011.58","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"6336_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.01.011","volume":"20","author":"F Bessone","year":"2022","unstructured":"Bessone F, Garc\u00eda-Cort\u00e9s M, Medina-Caliz I, Hernandez N, Parana R, Mendizabal M, Schinoni MI, Ridruejo E, Nunes V, Peralta M, Santos G, Anders M, Chiodi D, Tagle M, Montes P, Carrera E, Arrese M, Lizarzabal MI, Alvarez-Alvarez I, Caballano-Infantes E, Niu H, Pinazo J, Cabello MR, Lucena MI, Andrade RJ (2022) Herbal and dietary supplements-induced liver injury in Latin America: experience from the LATINDILI network. Clin Gastroenterol Hepatol 20(3):e548. https:\/\/doi.org\/10.1016\/j.cgh.2021.01.011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"6336_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A (2021) Inhibiting CDK4\/6 in breast cancer with Palbociclib, Ribociclib, and Abemaciclib: similarities and differences. Drugs 81(3):317\u2013331. https:\/\/doi.org\/10.1007\/s40265-020-01461-2","journal-title":"Drugs"},{"issue":"4","key":"6336_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40264-023-01390-5","volume":"47","author":"EB Cohen","year":"2024","unstructured":"Cohen EB, Patwardhan M, Raheja R, Alpers DH, Andrade RJ, Avigan MI, Lewis JH, Rockey DC, Chui F, Iacob AM, Linardi CC, Regev A, Shick J, Lucena MI (2024) Drug-induced liver injury in the elderly: consensus statements and recommendations from the IQ-DILI initiative. Drug Saf 47(4):301\u2013319. https:\/\/doi.org\/10.1007\/s40264-023-01390-5","journal-title":"Drug Saf"},{"issue":"4","key":"6336_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425\u2013439. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"6336_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/liv.12988","volume":"36","author":"L Dara","year":"2016","unstructured":"Dara L, Liu ZX, Kaplowitz N (2016) Mechanisms of adaptation and progression in idiosyncratic drug-induced liver injury: clinical implications. Liver Int 36(2):158\u2013165. https:\/\/doi.org\/10.1111\/liv.12988","journal-title":"Liver Int"},{"key":"6336_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.014","author":"EASL Clinical Practice Guidelines","year":"2019","unstructured":"EASL Clinical Practice Guidelines (2019) Drug-induced liver injury. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"issue":"9","key":"6336_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/fon-2017-0532","volume":"14","author":"E El Rassy","year":"2018","unstructured":"El Rassy E, Bakouny Z, Assi T, Kattan J (2018) Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference? Futur Oncol (Lond, Engl) 14(9):891\u2013895. https:\/\/doi.org\/10.2217\/fon-2017-0532","journal-title":"Futur Oncol (Lond, Engl)"},{"issue":"2","key":"6336_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/0284186X.2020.1853228","volume":"60","author":"S Finnsdottir","year":"2021","unstructured":"Finnsdottir S, Sverrisdottir A, Bj\u00f6rnsson ES (2021) Hepatotoxicity associated with ribociclib among breast cancer patients. Acta Oncol 60(2):195\u2013198. https:\/\/doi.org\/10.1080\/0284186X.2020.1853228","journal-title":"Acta Oncol"},{"issue":"12","key":"6336_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029361","volume":"12","author":"MG Fradley","year":"2023","unstructured":"Fradley MG, Nguyen NHK, Madnick D, Chen Y, DeMichele A, Makhlin I, Dent S, Lefebvre B, Carver J, Upshaw JN, DeRemer D, Ky B, Guha A, Gong Y (2023) Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer. J Am Heart Assoc 12(12):e029361. https:\/\/doi.org\/10.1161\/JAHA.123.029361","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"6336_CR12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, DeCristo MJ, McAllister SS, Zhao JJ (2018) CDK4\/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol 28(11):911\u2013925. https:\/\/doi.org\/10.1016\/j.tcb.2018.07.002","journal-title":"Trends Cell Biol"},{"issue":"3","key":"6336_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Bj\u00f6rnsson ES (2019) Drug-induced liver injury - types and phenotypes. N Engl J Med 381(3):264\u2013273. https:\/\/doi.org\/10.1056\/NEJMra1816149","journal-title":"N Engl J Med"},{"issue":"7","key":"6336_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O\u2019Shaughnessy J (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29(7):1541\u20131547. https:\/\/doi.org\/10.1093\/annonc\/mdy155","journal-title":"Ann Oncol"},{"issue":"3","key":"6336_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61030549","volume":"61","author":"N \u0130lhan","year":"2025","unstructured":"\u0130lhan N, Do\u011fan A, Er\u00f6lmez HN, Atalah F, Ba\u015f S, Yasar S, Odaba\u015f H, G\u00fcm\u00fc\u015f M (2025) The incidence and clinical characteristics of interstitial lung disease associated with CDK4\/6 inhibitors in breast cancer patients: a retrospective multicenter study. Medicina (Kaunas) 61(3):549. https:\/\/doi.org\/10.3390\/medicina61030549","journal-title":"Medicina (Kaunas)"},{"key":"6336_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2018.03.013","volume":"95","author":"E Jacquet","year":"2018","unstructured":"Jacquet E, Lardy-Cl\u00e9aud A, Pistilli B, Franck S, Cottu P, Delaloge S, Debled M, Vanlemmens L, Leheurteur M, Guizard AV, Laborde L, Uwer L, Jacot W, Berchery D, Desmoulins I, Ferrero JM, Perrocheau G, Courtinard C, Brain E, Chabaud S, Robain M, Bachelot T (2018) Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer 95:93\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2018.03.013","journal-title":"Eur J Cancer"},{"issue":"15 Suppl.","key":"6336_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e13037","volume":"39","author":"N Jahan","year":"2021","unstructured":"Jahan N, Wongsaengsak S, Rehman S, Adhikari N, Tijani LA, Raghunath A (2021) Relative risk of hepatotoxicity associated with cyclin-dependent kinase inhibitors (CDK4\/6i): a systematic review and meta-analysis of phase 3 randomized controlled trials. J Clin Oncol 39(15 Suppl.):e13037. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e13037","journal-title":"J Clin Oncol"},{"key":"6336_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"key":"6336_CR19","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1186\/s12885-024-13357-5","volume":"24","author":"S Kahraman","year":"2024","unstructured":"Kahraman S, Hizal M, Demirel BC et al (2024) Activity of CDK4\/6 inhibitors and parameters affecting survival in elderly patients in age subgroups: Turkish Oncology Group (TOG) retrospective study. BMC Cancer 24:1592. https:\/\/doi.org\/10.1186\/s12885-024-13357-5","journal-title":"BMC Cancer"},{"issue":"1","key":"6336_CR20","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v14i1.4989","volume":"14","author":"W Li","year":"2023","unstructured":"Li W, Wertheimer A (2023) Narrative review: the FDA\u2019s perfunctory approach of dietary supplement regulations giving rise to copious reports of adverse events. Innov Pharm 14(1):10.24926\/iip.v14i1.4989. https:\/\/doi.org\/10.24926\/iip.v14i1.4989","journal-title":"Innov Pharm"},{"key":"6336_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-024-00770-6","volume":"25","author":"W Lin","year":"2024","unstructured":"Lin W, Zeng Y, Weng L et al (2024) Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA\u2019s adverse event reporting system: a case-control pharmacovigilance study. BMC Pharmacol Toxicol 25:47. https:\/\/doi.org\/10.1186\/s40360-024-00770-6","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"6336_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","volume":"32","author":"M Martin","year":"2021","unstructured":"Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Mu\u00f1oz M, Bermejo B, Margeli M, Anton A, Kahan Z, Cs\u00f6szi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Gil-Gil M (2021) Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol 32(4):488\u2013499. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.013","journal-title":"Ann Oncol"},{"issue":"4","key":"6336_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/hep.27317","volume":"60","author":"VJ Navarro","year":"2014","unstructured":"Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J, Sherker AH, Stolz A, Talwalkar J, Vega M, Vuppalanchi R (2014) Liver injury from herbals and dietary supplements in the U.S. drug-induced liver injury Network. Hepatology 60(4):1399\u20131408. https:\/\/doi.org\/10.1002\/hep.27317","journal-title":"Hepatology"},{"issue":"1","key":"6336_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2024.2387323","volume":"24","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhou Y, Zhou X, Jia X, Zhong Y (2024) A disproportionality analysis of CDK4\/6 inhibitors in the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf 24(1):25\u201333. https:\/\/doi.org\/10.1080\/14740338.2024.2387323","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"6336_CR25","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.2015.2571","volume":"313","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Martin P, Lok AS (2015) Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA 313(16):1617\u20131618. https:\/\/doi.org\/10.1001\/jama.2015.2571","journal-title":"JAMA"},{"issue":"6","key":"6336_CR26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, Fontana RJ, Hayashi PH, US Drug-Induced Liver Injury Network (2010) Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (Baltimore, MD) 51(6):2117\u20132126. https:\/\/doi.org\/10.1002\/hep.23577","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"6336_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M (2021) Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist 26(1):e53. https:\/\/doi.org\/10.1002\/onco.13531","journal-title":"Oncologist"},{"issue":"1","key":"6336_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2022) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"6336_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"6","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart\u00edn M, Nusch A, Sonke GS, la De Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 6(6):514\u2013524. https:\/\/doi.org\/10.1056\/NEJMoa1911149","journal-title":"N Engl J Med"},{"issue":"25","key":"6336_CR30","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women With HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol Icial J Am Soc Clin Oncol 35(25):2875\u20132884. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585","journal-title":"J Clin Oncol Icial J Am Soc Clin Oncol"},{"key":"6336_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2468357","author":"Y Tang","year":"2025","unstructured":"Tang Y, Li Y, Zhang C, Ye Y, Qiu T, Zhu Z, Zhao J (2025) Hepatic adverse events with CDK4\/6 inhibitors: a systematic review combining meta-analysis and FAERS database. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2025.2468357","journal-title":"Expert Opin Drug Saf"},{"key":"6336_CR32","unstructured":"U.S. Food and Drug Administration (2009) Guidance for industry: drug-induced liver injury\u2014Premarketing clinical evaluation. [FDA Guidance Document]. Available via https:\/\/www.fda.gov\/media\/116737\/download"},{"issue":"7","key":"6336_CR33","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","volume":"90","author":"W Yeo","year":"2004","unstructured":"Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ (2004) Comprehensive analysis of risk factors associated with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90(7):1306\u20131311. https:\/\/doi.org\/10.1038\/sj.bjc.6601699","journal-title":"Br J Cancer"},{"key":"6336_CR34","doi-asserted-by":"publisher","first-page":"103256","DOI":"10.1016\/j.esmoop.2024.103256","volume":"9","author":"P Zagami","year":"2024","unstructured":"Zagami P, Esposito A, TaurelliSalimbeni B, BertonGiachetti PPM, Scafetta R, Lambertini M, Di Maio M, Curigliano G, Criscitiello C, Cinieri S (2024) 235P advancing treatment choices: CDK4\/6 inhibitor switching in HR+\/HER2- metastatic breast cancer. ESMO Open. 9:103256. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103256","journal-title":"ESMO Open."},{"issue":"1","key":"6336_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","volume":"147","author":"X Zhang","year":"2023","unstructured":"Zhang X (2023) Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med 147(1):46\u201351. https:\/\/doi.org\/10.5858\/arpa.2022-0070-RA","journal-title":"Arch Pathol Lab Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06336-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:46:50Z","timestamp":1761338810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6336"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06336-1","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Sancaktepe \u015eehit Prof. Dr. \u0130lhan Varank Training and Research Hospital (Approval number: 2024\/300; Approval date: 18 September 2024). All participants provided written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"270"}}